Acura Pharma (ACUR) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results
February 29, 2016 4:30 PM ESTPALATINE, IL -- (Marketwired) -- 02/29/16 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2015.
The Company reported a net loss of $5.0 million or $0.46 per diluted share for 2015 compared to a net loss of $13.2 million or $1.35 per diluted share for 2014. For the fourth quarter ended December 31, 2015 the Company reported a net loss of $0.9 million or $0.08 per diluted share, compared to net loss of $2.7 million or $0.30 per diluted share for the same period in 2014.
For the twelve months ended... More
